About Corcept
Corcept is a company based in Menlo Park (United States) founded in 1998.. The company has 500 employees as of December 31, 2024. Corcept offers products and services including Cortisol Modulation Pipeline. Corcept operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, ViaCyte and 89bio, among others.
- Headquarter Menlo Park, United States
- Employees 500 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Corcept Therapeutics Incorporated
-
Annual Revenue
$675.04 M39.94as on Dec 31, 2024
-
Net Profit
$139.73 M32.45as on Dec 31, 2024
-
EBITDA
$138.29 M27.66as on Dec 31, 2024
-
Latest Funding Round
-
Investors
Investor Growth Capital
& 4 more
-
Employee Count
500
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Corcept
Corcept is a publicly listed company on the NASDAQ with ticker symbol CORT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Corcept
Corcept offers a comprehensive portfolio of products and services, including Cortisol Modulation Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments for diseases affected by cortisol through clinical trials.
Unlock access to complete
Unlock access to complete
Sales and Marketing
41 people
Leadership Team
36 people
Software Development Team
13 people
Finance and Accounting
13 people
Product Management Team
12 people
Senior Team
8 people
Operations Team
8 people
Data Analysis and Operations Team
7 people
Unlock access to complete
Funding Insights of Corcept
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(15 Nov 2006)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2011 | Amount | Post-IPO - Corcept | Valuation |
investors |
|
| Apr, 2010 | Amount | Post-IPO - Corcept | Valuation |
investors |
|
| Oct, 2009 | Amount | Post-IPO - Corcept | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Corcept
Corcept has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Investor Growth Capital, Longitude Capital and Sutter Hill Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location | |
|
VC firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Corcept
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Corcept
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Corcept Comparisons
Competitors of Corcept
Corcept operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, ViaCyte and 89bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Corcept
Frequently Asked Questions about Corcept
When was Corcept founded?
Corcept was founded in 1998 and raised its 1st funding round 8 years after it was founded.
Where is Corcept located?
Corcept is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
How many employees does Corcept have?
As of Dec 31, 2024, the latest employee count at Corcept is 500.
What is the annual revenue of Corcept?
Annual revenue of Corcept is $675.04M as on Dec 31, 2024.
What does Corcept do?
Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.
Who are the top competitors of Corcept?
Corcept's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
What products or services does Corcept offer?
Corcept offers Cortisol Modulation Pipeline.
Is Corcept publicly traded?
Yes, Corcept is publicly traded on NASDAQ under the ticker symbol CORT.
Who are Corcept's investors?
Corcept has 5 investors. Key investors include Investor Growth Capital, Longitude Capital, Sutter Hill Ventures, Alta Partners, and Paperboy Ventures.
What is Corcept's ticker symbol?
The ticker symbol of Corcept is CORT on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.